American Healthcare REIT Inc (AHR) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate AHR’s ability to generate resilient cash flow while strengthening its balance sheet, positioning the REIT for continued dividend appeal and growth in a high‑demand outpatient medical market.

Key Takeaways

• Normalized FFO beats guidance, showing resilient earnings
• Leasing activity adds 5.8M sq ft, boosting occupancy
• Debt-to-EBITDA falls to 5.4x, enhancing financial flexibility
• Commercial paper $600M diversifies funding, cuts interest expense
• Dividend reset to ~6% yield, 75% payout ratio

Pulse Analysis

The outpatient medical real estate market continues to outpace new supply, driven by health systems expanding ambulatory services and patients favoring convenient care locations. American Healthcare REIT (AHR) leverages this macro trend with a portfolio concentrated in high‑growth MSAs, where occupancy remains above 94% and tenant demand is strong. Recent leasing activity—5.8 million square feet of new and renewed space—reflects deep relationships with leading health providers such as Tufts Medicine and Baptist Health. As the sector’s cap rates compress, AHR’s ability to secure long‑term, escalator‑laden leases positions it for sustainable rent growth.

Financially, AHR delivered normalized FFO of $1.61 per share, edging past the midpoint of its guidance, while same‑store NOI rose 4.8% year‑over‑year. The company’s disciplined expense program trimmed G&A to $45 million and improved property NOI margins by 60 basis points. Leverage improved dramatically, with net debt‑to‑EBITDA dropping to 5.4x after $900 million of debt repayments and extended maturities. Capital allocation emphasized shareholder returns—a $50 million share repurchase and a newly launched $600 million commercial paper program that diversifies funding sources and reduces borrowing costs.

Looking ahead, AHR’s 2026 guidance projects flat normalized FFO but embeds roughly 5% core earnings growth, offset by the 2025 disposition tail. The firm’s redevelopment pipeline, delivering yields on cost near 10%, is expected to generate incremental NOI after 2026, reinforcing the earnings outlook. With a dividend reset at a near‑6% yield and a 75% payout ratio, the REIT offers attractive cash flow to investors, provided interest‑rate volatility does not erode the commercial paper advantage. Continued health‑system partnerships and selective joint‑venture opportunities will be key to sustaining growth in a capital‑intensive environment.